HURA · TuHURA Biosciences, Inc.

TuHURA Biosciences reported a GAAP net loss of -$7.5 million for Q1 FY2026, representing a 13.1% widening from -$6.7 million in the prior-year quarter. This reflects the Company's ongoing investment in research and development activities related to Immune Fx, TBS-2025, and antibody-drug conjugates (ADCs), which require substantial capital until revenue generation begins. Diluted EPS improved to -$0.13 from -$0.15 year-over-year, a 13.3% enhancement attributable to the per-share impact of equity issuances that increased the share count while losses grew in absolute terms.

Liquidity remains a focal point, with management noting that the Company has incurred net losses and negative operating cash flows since inception and anticipates continuation into the foreseeable future. Projections of capital needs are based on the current operating plan, including assumptions around R&D timelines that may prove incorrect, potentially accelerating resource depletion. To address this, the Company expects to raise cash through capital stock and warrants sales, debt, grants, or partnerships. Existing capital resources, including anticipated proceeds from the revolving line of credit with Parkview Holdings One LLC, are projected sufficient to fund planned operations into the end of 2028. However, inability to draw sufficient funds under this facility could adversely impact financial position and development activities.

These dynamics underscore TuHURA's clinical-stage focus, where R&D intensity drives losses but positions the pipeline for potential future value. Investors should monitor execution against the operating plan and credit facility access, as deviations could pressure liquidity sooner than anticipated.